Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis

Cell Adhesion and Migration

Volumn 9, Issue 4, 2015, Pages 265-276

  Neelakantan, Deepika ^a   Drasin, David J ^a   Ford, Heide L ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells CSCs; Clonal evolution; Epithelial mesenchymal transition (EMT); Intratumoral heterogeneity; Metastasis; Non cell autonomous; Tumor microenvironment

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; WNT1 PROTEIN;

ARTICLE; CANCER STEM CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL HETEROGENEITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; LYMPHATIC LEUKEMIA; METASTASIS; NEXT GENERATION SEQUENCING; NONHUMAN; NUTRIENT AVAILABILITY; TUMOR GROWTH; TUMOR MICROENVIRONMENT; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CELL DIFFERENTIATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASTIC STEM CELLS;

EID: 84954201325     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/19336918.2014.972761     Document Type: Article

References (129)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8; PMID: 959840; http: //dx. doi. org/10. 1126/science. 959840
2. Fialkow PJ. Clonal origin of human tumors. Biochim Biophys Acta 1976; 458: 283-321; PMID: 1067873
3. Lyons JG, Lobo E, Martorana AM, Myerscough MR. Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions. Clin Exp Metastasis 2008; 25: 665-77; PMID: 18071912; http: //dx. doi. org/10. 1007/s10585-007-9134-2
4. Parsons BL. Monoclonal tumor origin is an underlying misconception of the RESIC approach. Proc Natl Acad Sci U S A 2011; 108: E15; author reply E6; PMID: 21239682; http: //dx. doi. org/10. 1073/pnas. 1017998108
5. Parsons BL. Many different tumor types have polyclonal tumor origin: evidence and implications. Mutat Res 2008; 659: 232-47; PMID: 18614394; http: //dx. doi. org/10. 1016/j. mrrev. 2008. 05. 004
6. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, Kempski H, Moorman AV, Titley I, Swansbury J, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-61; PMID: 21160474; http: // dx. doi. org/10. 1038/nature09650
7. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-4; PMID: 21399628; http: //dx. doi. org/10. 1038/nature09807
8. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92; PMID: 22397650; http: //dx. doi. org/10. 1056/NEJMoa1113205
9. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978; 38: 2651-60; PMID: 354778
10. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem 2013; 59: 168-79; PMID: 23220226; http: //dx. doi. org/10. 1373/clinchem. 2012. 184655
11. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009; 138: 822-9; PMID: 19737509; http: //dx. doi. org/10. 1016/j. cell. 2009. 08. 017
12. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12: 323-34; PMID: 22513401; http: //dx. doi. org/10. 1038/nrc3261
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell; 144: 646-74; PMID: 21376230; http: //dx. doi. org/10. 1016/j. cell. 2011. 02. 013
14. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-26; PMID: 23415222; http: //dx. doi. org/10. 1016/j. cell. 2013. 01. 019
15. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-45; PMID: 24048066; http: //dx. doi. org/10. 1038/nature 12625
16. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-63; PMID: 22817889; http: //dx. doi. org/10. 1016/j. cell. 2012. 06. 024
17. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-9; PMID: 22495314
18. Rosai J, Ackerman LV. The pathology of tumors, part III: grading, staging & classification. CA: Cancer J Clin 1979; 29: 66-77; PMID: 219944; http: //dx. doi. org/10. 1017/S0009838800035175
19. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 2012; 109: 3041-6; PMID: 22323597; http: //dx. doi. org/10. 1073/pnas. 1114033109
20. HeppnerGH, Dexter DL, DeNucci T, Miller FR, Calabresi P. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res 1978; 38: 3758-63; PMID: 698935
21. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AM, Ng K, Ma J, Wienholds E, Dunant C, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013; 339: 543-8; PMID: 23239622; http: //dx. doi. org/10. 1126/science. 1227670
22. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, Croul S, Bouffet E, Fults DW, Eberhart CG, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012; 482: 529-33; PMID: 22343890; http: //dx. doi. org/10. 1038/ nature10825
23. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-405; PMID: 1540948
24. Harbst K, Lauss M, Cirenajwis H, Winter C, Howlin J, Torngren T, Kvist A, Nodin B, Olsson E, Hakkinen J, et al. Molecular and genetic diversity in the metastatic process of melanoma. J Pathol 2014; 233: 39-50; PMID: 24399611
25. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014; 28: 384-90; PMID: 23817176; http: //dx. doi. org/10. 1038/leu. 2013. 199
26. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501: 328-37; PMID: 24048065; http: //dx. doi. org/10. 1038/nature 12624
27. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-13; PMID: 22258609; http: // dx. doi. org/10. 1038/nature10762
28. Crockford A, Jamal-Hanjani M, Hicks J, Swanton C. Implications of intratumour heterogeneity for treatment stratification. J Pathol 2014; 232: 264-73; PMID: 24115146; http: //dx. doi. org/ 10. 1002/path. 4270
29. Spremulli EN, Dexter DL. Human tumor cell heterogeneity and metastasis. J Clin Oncol 1983; 1: 496-509; PMID: 6366142
30. Junttila MR, de Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature 2013; 501: 346-54; PMID: 24048067; http: //dx. doi. org/10. 1038/nature12626
31. Marusyk A, Polyak K. Cancer. Cancer cell phenotypes, in fifty shades of grey. Science 2013; 339: 528-9; PMID: 23372002; http: //dx. doi. org/10. 1126/ science. 1234415
32. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805: 105-17; PMID: 9931353
33. Charles N, Ozawa T, SquatritoM, Bleau AM, Brennan CW, Hambardzumyan D, Holland EC. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010; 6: 141-52; PMID: 20144787; http: //dx. doi. org/10. 1016/j. stem. 2010. 01. 001
34. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12: 468-76; PMID: 20418870; http: //dx. doi. org/10. 1038/ ncb2048
35. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011; 121: 3804-9; PMID: 21965337; http: //dx. doi. org/10. 1172/JCI57099
36. Fabian A, Vereb G, Szollosi J. The hitchhikers guide to cancer stem cell theory: markers, pathways and therapy. Cytometry A 2013; 83: 62-71; PMID: 22997049; http: //dx. doi. org/10. 1002/cyto. a. 22206
37. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013; 2: 3; PMID: 23369605; http: //dx. doi. org/10. 1186/2001-1326-2-3
38. Tomao F, Papa A, Strudel M, Rossi L, Lo Russo G, Benedetti Panici P, Ciabatta FR, Tomao S. Investigating molecular profiles of ovarian cancer: an update on cancer stem cells. J Cancer 2014; 5: 301-10; PMID: 24723972; http: //dx. doi. org/10. 7150/jca. 8610
39. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15; PMID: 18485877; http: //dx. doi. org/ 10. 1016/j. cell. 2008. 03. 027
40. Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol 2012; 198: 281-93; PMID: 22869594; http: //dx. doi. org/10. 1083/ jcb. 201202014
41. Kang Y. Analysis of cancer stem cell metastasis in xenograft animal models. Methods Mol Biol 2009; 568: 7-19; PMID: 19582418; http: //dx. doi. org/ 10. 1007/978-1-59745-280-9_2
42. Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 2007; 449: 473-7; PMID: 17851532; http: //dx. doi. org/10. 1038/nature 06159
43. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008; 3: e2888; PMID: 18682804; http: //dx. doi. org/ 10. 1371/journal. pone. 0002888
44. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. ProcNatl Acad Sci U S A 2011; 108: 7950-5; PMID: 21498687; http: //dx. doi. org/10. 1073/pnas. 1102454108
45. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 2011; 108: 1397-402; PMID: 21220315; http: //dx. doi. org/ 10. 1073/pnas. 1018898108
46. Yu CC, Lo WL, Chen YW, Huang PI, Hsu HS, Tseng LM, Hung SC, Kao SY, Chang CJ, Chiou SH. Bmi-1 regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells. J oOcol 2011; 2011: pii: 609259; PMID: 20936121
47. Kim SY, Kang JW, Song X, Kim BK, Yoo YD, Kwon YT, Lee YJ. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal 2013; 25: 961-9; PMID: 23333246; http: //dx. doi. org/10. 1016/j. cellsig. 2013. 01. 007
48. Martelotto LG, Ng CK, Piscuoglio S, Weigelt B, Reis-Filho JS. Breast cancer intra-tumor heterogeneity. Breast Cancer Res 2014; 16: 210; http: //dx. doi. org/ 10. 1186/bcr3658
49. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11: 259-73; PMID: 17349583; http: //dx. doi. org/10. 1016/j. ccr. 2007. 01. 013
50. Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA, Ma J, Minden MD, Downing JR, Dick JE. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469: 362-7; PMID: 21248843; http: //dx. doi. org/ 10. 1038/nature09733
51. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 2011; 13: 202; PMID: 21392411; http: //dx. doi. org/10. 1186/bcr2789
52. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012; 22: 709-24; PMID: 23201163; http: //dx. doi. org/10. 1016/j. ccr. 2012. 10. 012
53. Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, Yang J. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011; 19: 372-86; PMID: 21397860; http: //dx. doi. org/10. 1016/j. ccr. 2011. 01. 036
54. Kanzawa M, Semba S, Hara S, Itoh T, Yokozaki H. WNT5A is a key regulator of the epithelial-mesenchymal transition and cancer stem cell properties in human gastric carcinoma cells. Pathobiology 2013; 80: 235-44; PMID: 23615002; http: //dx. doi. org/ 10. 1159/000346843
55. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90; PMID: 19945376; http: //dx. doi. org/10. 1016/j. cell. 2009. 11. 007
56. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339: 580-4; PMID: 23372014; http: //dx. doi. org/10. 1126/science. 1228522
57. Fomchenko EI, Dougherty JD, Helmy KY, Katz AM, Pietras A, Brennan C, Huse JT, Milosevic A, Holland EC. Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. PloS one 2011; 6: e20605; PMID: 21754979; http: //dx. doi. org/10. 1371/journal. pone. 0020605
58. Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 2014; 508: 113-7; PMID: 24695311; http: //dx. doi. org/10. 1038/nature13187
59. Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, Fan F, Dallas N, Xia L, Gaur P, et al. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. British journal of cancer 2011; 105: 1759-67; PMID: 22045189; http: //dx. doi. org/ 10. 1038/bjc. 2011. 449
60. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805: 105-17; PMID: 19931353
61. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006; 6: 449-58; PMID: 16723991; http: //dx. doi. org/10. 1038/nrc1886
62. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-72; PMID: 12154349; http: //dx. doi. org/10. 1038/nrc865
63. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5: 591-602; PMID: 16056258; http: //dx. doi. org/10. 1038/nrc1670
64. Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang J, Mehra R, Keller ET, et al. An in vivo mouse model for human prostate cancer metastasis. Neoplasia 2008; 10: 371-80; PMID: 18392141
65. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002; 8: 3468-74; PMID: 12429636
66. Bernards R, Weinberg RA. A progression puzzle. Nature 2002; 418: 823; PMID: 12192390; http: //dx. doi. org/10. 1038/418823a
67. Weiss L, Holmes JC, Ward PM. Do metastases arise from pre-existing subpopulations of cancer cells? Br J Cancer 1983; 47: 81-9; PMID: 6571784; http: //dx. doi. org/10. 1038/bjc. 1983. 10
68. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893-5; PMID: 887927; http: //dx. doi. org/ 10. 1126/science. 887927
69. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6; PMID: 11823860; http: //dx. doi. org/10. 1038/415530a
70. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54; PMID: 12469122; http: //dx. doi. org/10. 1038/ng1060
71. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992; 326: 1756-61; PMID: 1594018; http: //dx. doi. org/10. 1056/NEJM199206253262607
72. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sanchez V, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014; 4: 232-45; PMID: 24356096; http: //dx. doi. org/10. 1158/2159-8290. CD-13-0286
73. StoeckleinNH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer 2010; 126: 589-98; PMID: 19795462; http: //dx. doi. org/10. 1002/ijc. 24916
74. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-37; PMID: 24202395; http: //dx. doi. org/ 10. 1038/nm. 3394
75. Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA, Krizhanovsky V, et al. Non-cell-autonomous tumor suppression by p53. Cell 2013; 153: 449-60; PMID: 23562644; http: //dx. doi. org/10. 1016/j. cell. 2013. 03. 020
76. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-51; PMID: 14764882; http: //dx. doi. org/10. 1126/science. 1090922
77. Miller FR. Tumor subpopulation interactions in metastasis. Invasion Metastasis 1983; 3: 234-42; PMID: 6677628
78. Miller FR, Heppner GH. Cellular interactions in metastasis. Cancer Metastasis Rev 1990; 9: 21-34; PMID: 2208566; http: //dx. doi. org/10. 1007/BF000 47586
79. Miller BE, Miller FR, Leith J, Heppner GH. Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor. Cancer Res 1980; 40: 3977-81; PMID: 7471048
80. Miller BE, Miller FR, Wilburn D, Heppner GH. Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. Cancer Res 1988; 48: 5747-53; PMID: 3167832
81. Poste G, Doll J, Fidler IJ. Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci U S A 1981; 78: 6226-30; PMID: 6947225; http: //dx. doi. org/10. 1073/pnas. 78. 10. 6226
82. Baban D, Matsumura Y, Kocialkowski S, Tarin D. Studies on relationships between metastatic and nonmetastatic tumor cell populations using lineages labeled with dominant selectable genetic markers. Int J Dev Biol 1993; 37: 237-43; PMID: 8507566
83. Hao S, Ye Z, Li F, Meng Q, Qureshi M, Yang J, Xiang J. Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cellreleased exosomes. Exp Oncol 2006; 28: 126-31; PMID: 16837903
84. Calbo J, van Montfort E, Proost N, van Drunen E, Beverloo HB, Meuwissen R, Berns A. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 2011; 19: 244-56; PMID: 21316603; http: //dx. doi. org/10. 1016/j. ccr. 2010. 12. 021
85. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-8; PMID: 19487818; http: //dx. doi. org/10. 1172/JCI39104
86. Drasin DJ, Robin TP, Ford HL. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res 2011; 13: 226; PMID: 22078097; http: //dx. doi. org/ 10. 1186/bcr3037
87. Hay ED, Zuk A. Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am J Kidney Dis 1995; 26: 678-90; PMID: 7573028; http: //dx. doi. org/10. 1016/0272-6386(95)90610-X
88. Shook D, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mechanisms Dev 2003; 120: 1351-83; PMID: 14623443; http: //dx. doi. org/10. 1016/j. mod. 2003. 06. 005
89. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22: 725-36; PMID: 23201165; http: //dx. doi. org/10. 1016/j. ccr. 2012. 09. 022
90. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006; 66: 11271-8; PMID: 17145872; http: //dx. doi. org/ 10. 1158/0008-5472. CAN-06-2044
91. Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 2007; 185: 7-19; PMID: 17587803; http: //dx. doi. org/10. 1159/ 000101298
92. Ford HL, Thompson EW. Mammary gland studies as important contributors to the cause of epithelial mesenchymal plasticity in malignancy. J Mammary Gland Biol Neoplasia 2010; 15: 113-5; PMID: 20544376; http: //dx. doi. org/10. 1007/s10911-010-9182-0
93. Micalizzi DS, Farabaugh SM, Ford HL. Epithelialmesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010; 15: 117-34; PMID: 20490631; http: //dx. doi. org/10. 1007/s10911-010-9178-9
94. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009; 60: 167-79; PMID: 19630570; http: //dx. doi. org/10. 1146/annurev. med. 59. 053006. 104707
95. Bhaskaran M, Mohan M. MicroRNAs: History, Biogenesis, and Their Evolving Role in Animal Development and Disease. Vet Path 2013; 51: 759-774; PMID: 24045890
96. Brade T, Manner J, Kuhl M. The role of Wnt signalling in cardiac development and tissue remodelling in the mature heart. Cardiovasc Res 2006; 72: 198-209; PMID: 16860783; http: //dx. doi. org/ 10. 1016/j. cardiores. 2006. 06. 025
97. Erson AE, Petty EM. MicroRNAs in development and disease. Clin Genet 2008; 74: 296-306; PMID: 18713256; http: //dx. doi. org/10. 1111/j. 1399-0004. 2008. 01076. x
98. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011; 91: 827-87; PMID: 21742789; http: //dx. doi. org/10. 1152/physrev. 00006. 2010
99. Hornstein E, Shomron N. Canalization of development by microRNAs. Nat Genet 2006; 38 Suppl: S20-4; PMID: 16736020; http: //dx. doi. org/10. 1038/ ng1803
100. Hornstein E, Mansfield JH, Yekta S, Hu JK, Harfe BD, McManus MT, Baskerville S, Bartel DP, Tabin CJ. The microRNA miR-196 acts upstream of Hoxb8 and Shh in limb development. Nature 2005; 438: 671-4; PMID: 16319892; http: //dx. doi. org/ 10. 1038/nature04138
101. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-50; PMID: 17011485; http: // dx. doi. org/10. 1016/j. devcel. 2006. 09. 009
102. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004; 304: 594-6; PMID: 15105502; http: //dx. doi. org/10. 1126/ science. 1097434
103. Srivastava SP, Koya D, Kanasaki K. MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and EndMT. BioMed Res Int 2013; 2013: 125469; PMID: 24089659; http: //dx. doi. org/ 10. 1155/2013/125469
104. Zhao X, Lu Y, Nie Y, Fan D. MicroRNAs as critical regulators involved in regulating epithelial-mesenchymal transition. Curr Cancer Drug Targets 2013; 13: 935-44; PMID: 24168189; http: //dx. doi. org/ 10. 2174/15680096113136660099
105. Hao J, Zhang Y, Deng M, Ye R, Zhao S, Wang Y, Li J, Zhao Z. MicroRNA control of epithelial-mesenchymal transition in cancer stem cells. Int J Cancer 2014; 135: 1019-27; PMID: 24500893
106. Wu MY, Hill CS. Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell 2009; 16: 329-43; PMID: 19289080; http: //dx. doi. org/10. 1016/j. devcel. 2009. 02. 012
107. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810; PMID: 15473860; http: //dx. doi. org/10. 1146/annurev. cellbio. 20. 010403. 113126
108. Christensen KL, Patrick AN, McCoy EL, Ford HL. The six family of homeobox genes in development and cancer. Adv Cancer Res 2008; 101: 93-126; PMID: 19055944; http: //dx. doi. org/10. 1016/S0065-230X(08)00405-3
109. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 2010; 107: 15449-54; PMID: 20713713; http: //dx. doi. org/ 10. 1073/pnas. 1004900107
110. Garg M. Epithelial-mesenchymal transition-activating transcription factors-multifunctional regulators in cancer. World J Stem Cells 2013; 5: 188-95; PMID: 24179606; http: //dx. doi. org/10. 4252/wjsc. v5. i4. 188
111. Palma J, Yaddanapudi SC, Pigati L, Havens MA, Jeong S, Weiner GA, Weimer KM, Stern B, Hastings ML, Duelli DM. MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res 2012; 40: 9125-38; PMID: 22772984; http: //dx. doi. org/10. 1093/nar/gks656
112. Demory Beckler M, Higginbotham JN, Franklin JL, Ham AJ, Halvey PJ, Imasuen IE, Whitwell C, Li M, Liebler DC, Coffey RJ. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics 2013; 12: 343-55; PMID: 23161513; http: // dx. doi. org/10. 1074/mcp. M112. 022806
113. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21; PMID: 18589210; http: //dx. doi. org/10. 1016/j. ygyno. 2008. 04. 033
114. Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, et al. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem 2012; 287: 34970-8; PMID: 22927443; http: // dx. doi. org/10. 1074/jbc. M112. 374611
115. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 2010; 107: 15449-54; PMID: 20713713; http: //dx. doi. org/ 10. 1073/pnas. 1004900107
116. Dhasarathy A, Phadke D, Mav D, Shah RR, Wade PA. The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer. PloS One 2011; 6: e26514; PMID: 22028892; http: //dx. doi. org/10. 1371/journal. pone. 0026514
117. Smith AP, Verrecchia A, Faga G, Doni M, Perna D, Martinato F, Guccione E, Amati B. A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 2009; 28: 422-30; PMID: 18978814; http: //dx. doi. org/ 10. 1038/onc. 2008. 395
118. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 2013; 27: 2192-206; PMID: 24142872; http: //dx. doi. org/10. 1101/gad. 225334. 113
119. Jing Y, Han Z, Zhang S, Liu Y, Wei L. Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci 2011; 1: 29; PMID: 21880137; http: //dx. doi. org/10. 1186/2045-3701-1-29
120. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 2012; 72: 4883-9; PMID: 23002209; http: //dx. doi. org/ 10. 1158/0008-5472. CAN-12-1223
121. Junk DJ, Cipriano R, Bryson BL, Gilmore HL, Jackson MW. Tumor microenvironmental signaling elicits epithelial-mesenchymal plasticity through cooperation with transforming genetic events. Neoplasia 2013; 15: 1100-9; PMID: 24027434
122. Martorana AM, Zheng G, Crowe TC, O'Grady RL, Lyons JG. Epithelial cells up-regulate matrix metalloproteinases in cells within the same mammary carcinoma that have undergone an epithelial-mesenchymal transition. Cancer Res 1998; 58: 4970-9; PMID: 9810007
123. Zheng G, Lyons JG. Cyclosporin A improves the selection of cells transfected with the puromycin acetyltransferase gene. BioTechniques 2002; 33: 32, 34, 36; PMID: 12139252
124. Lyons JG, Siew K, O'Grady RL. Cellular interactions determining the production of collagenase by a rat mammary carcinoma cell line. Int J Cancer 1989; 43: 119-25; PMID: 2536004; http: //dx. doi. org/ 10. 1002/ijc. 2910430123
125. Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, Hu GF. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 2008; 68: 10377-86; PMID: 19074907; http: //dx. doi. org/10. 1158/0008-5472. CAN-08-1444
126. Celia-Terrassa T, Meca-Cortes O, Mateo F, de Paz AM, Rubio N, Arnal-Estape A, Ell BJ, Bermudo R, Diaz A, Guerra-Rebollo M, et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest; 2012; 122: 1849-68; PMID: 22505459; http: //dx. doi. org/10. 1172/JCI59218
127. Axelrod R, Axelrod DE, Pienta KJ. Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A 2006; 103: 13474-9; PMID: 16938860; http: //dx. doi. org/10. 1073/pnas. 0606053103
128. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-46; PMID: 17957189; http: //dx. doi. org/ 10. 1038/nrc2256
129. Bragado P, Sosa MS, Keely P, Condeelis J, Aguirre-Ghiso JA. Microenvironments dictating tumor cell dormancy. Recent Results Cancer Res 2012; 195: 25-39; PMID: 22527492